Scarica l'app Stockscreener
13.90
1.61%
0.22
Dopo l'orario di chiusura:
13.65
-0.25
-1.80%
Panoramica
Notizia
Cronologia dei prezzi
Financials
Perché TNXP Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$13.68
Aprire:
$13.16
Volume 24 ore:
313.03K
Relative Volume:
0.73
Capitalizzazione di mercato:
$197.46M
Reddito:
$13.11M
Utile/perdita netta:
$-124.02M
Rapporto P/E:
-0.9747
EPS:
-14.261
Flusso di cassa netto:
$-107.25M
1 W Prestazione:
+1.09%
1M Prestazione:
-0.57%
6M Prestazione:
-43.77%
1 anno Prestazione:
-20.07%
Intervallo 1D:
$13.07
$14.01
Intervallo di 1 settimana:
$11.60
$14.90
Portata 52W:
$11.60
$69.97
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Company Profile
Nome
Tonix Pharmaceuticals Holding Corp
Settore
Industria
Telefono
212-980-9155
Indirizzo
200 CONNELL DRIVE, SUITE 3100, BERKELEY HEIGHTS, NY
Compare TNXP vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TNXP
Tonix Pharmaceuticals Holding Corp
|
13.90 | 197.46M | 13.11M | -124.02M | -107.25M | -14.26 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2022-04-18 | Iniziato | Noble Capital Markets | Outperform |
| 2019-04-18 | Aggiornamento | ROTH Capital | Neutral → Buy |
| 2017-08-18 | Aggiornamento | ROTH Capital | Neutral → Buy |
| 2016-09-07 | Downgrade | ROTH Capital | Buy → Neutral |
| 2016-02-17 | Reiterato | Oppenheimer | Outperform |
| 2015-11-04 | Iniziato | Cantor Fitzgerald | Buy |
| 2015-06-12 | Iniziato | Oppenheimer | Outperform |
| 2015-02-17 | Reiterato | ROTH Capital | Buy |
| 2014-09-29 | Reiterato | ROTH Capital | Buy |
Mostra tutto
Tonix Pharmaceuticals Holding Corp Borsa (TNXP) Ultime notizie
Tonix Pharmaceuticals stock hits new 52-week low: What's driving the action? - MSN
Tonix Pharmaceuticals Holding Corp at TD Cowen Healthcare Conference Transcript - GuruFocus
TNXP Stock Price, Quote & Chart | TONIX PHARMACEUTICALS HOLDIN (NASDAQ:TNXP) - ChartMill
Tonix Pharma CEO Lederman buys $63,099 in shares By Investing.com - Investing.com Canada
Tonix Pharma CEO Lederman buys $63,099 in shares - Investing.com
Tonix (NASDAQ: TNXP) CEO adds 5,000 shares via IRA purchase - Stock Titan
Tonix Pharmaceuticals Holding Corp. (TNXP) stock price, news, quote and history - Yahoo Finance Australia
Tonix plans Phase 2 Lyme disease prevention study in 2027 By Investing.com - au.investing.com
Tonix Pharmaceuticals Holding Corp Presents Phase 1 Data And Outlines Planned Adaptive Phase 2 Field Study Of TNX-4800 For Prevention Of Lyme Disease - MarketScreener
Tonix Pharma Advances TNX-4800 Lyme Disease Prevention Program - TipRanks
Tonix Pharmaceuticals (TNXP) Advances TNX-4800 Lyme Disease Trea - GuruFocus
Tonix plans Phase 2 Lyme disease prevention study in 2027 - Investing.com
Tonix Pharmaceuticals presents Phase 1 TNX-4800 data, aims for adaptive Phase 2 in H1 2027 - TradingView
Tonix (Nasdaq: TNXP) advances TNX-4800 Lyme prevention antibody on Phase 1 data - Stock Titan
No U.S. Lyme preventive exists; Tonix tests 4-month single dose - Stock Titan
Tonix Pharmaceuticals Announces Presentation of Phase 1 Data and Outlines Planned Adaptive Phase 2 Field Study of TNX-4800 for the Prevention of Lyme Disease, at the World Vaccine Congress Washington 2026 - Bitget
Recap Report: Can Tonix Pharmaceuticals Holding Corp stock outperform in a bear marketAnalyst Upgrade & Risk Controlled Stock Pick Alerts - baoquankhu1.vn
Tonix Pharmaceuticals Stock Hits New 52-Week Low: What's Driving The Action? - Benzinga
Tonix Pharmaceuticals (NASDAQ: TNXP) puts reverse split and 2026 equity plan to vote - Stock Titan
TNXP Should I Buy - Intellectia AI
TNXP SEC FilingsTonix Pharmaceut 10-K, 10-Q, 8-K Forms - Stock Titan
Tonix Pharmaceuticals (NASDAQ:TNXP) Rating Lowered to "Sell" at Wall Street Zen - MarketBeat
Vanguard disaggregates holdings after realignment; reports 0 shares in Tonix (TNXP) - Stock Titan
Tonix Pharmaceuticals Holding Corp. Trade Ideas — BOATS:TNXP - TradingView
Tonix doses first patient in migraine treatment study By Investing.com - za.investing.com
Tonix Pharmaceuticals Begins Phase 1 Study of Intranasal Oxytocin (TNX-1900) for Migraine and Craniofacial Pain Treatment - Minichart
Tonix Pharmaceuticals Announces First Participant Dosed in Phase 1 Investigator-Initiated Pharmacodynamic Study of TNX-1900 (Intranasal Potentiated Oxytocin) to Assess Potential for Treating Migraine and Craniofacial Pain - Bitget
Tonix Pharmaceuticals (TNXP) Advances with Phase 1 Study on TNX-1900 - gurufocus.com
Tonix Pharma Begins Phase 1 Study of TNX-1900 - TipRanks
Tonix doses first patient in migraine treatment study - Investing.com
Tonix (NASDAQ: TNXP) doses first subject in TNX-1900 migraine study - Stock Titan
Tonix Pharmaceuticals Holding Corp Announces First Participant Dosed in Phase 1 Investigator-Initiated Pharmacodynamic Study of TNX-1900 - MarketScreener
Q1 Earnings Forecast for TNXP Issued By Zacks Research - MarketBeat
FY2028 Earnings Estimate for TNXP Issued By Zacks Research - Defense World
Why (TNXP) Price Action Is Critical for Tactical Trading - news.stocktradersdaily.com
FY2028 Earnings Forecast for TNXP Issued By Zacks Research - MarketBeat
Tonix Pharmaceuticals Holding Corp. (TNXP) Presents at BIO-Europe Spring 2026Slideshow - Seeking Alpha
TNXP: ~2500 Patients Have Initiated Treatment with Tonmya Following November 2025 Commercial Launch - research-tree.com
Tonix Pharmaceuticals Announces Presentations at World Vaccine Congress Washington 2026 - The Manila Times
Tonix Pharmaceuticals Announces Upcoming Presentations on TNX-4800 and TNX-801 at World Vaccine Congress 2026 - Quiver Quantitative
Lyme disease and mpox studies put Tonix on vaccine congress agenda - Stock Titan
Levels Update: What are Tonix Pharmaceuticals Holding Corps earnings expectationsEarnings Performance Report & Free Technical Confirmation Trade Alerts - baoquankhu1.vn
Tonix Pharmaceuticals (NASDAQ: TNXP) Seeks 1:2–1:250 Reverse Split; PwC Ratification - Stock Titan
Tonix Pharmaceuticals Holding Corp. Trade Ideas — LSX:A40VM0 - TradingView
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Tonix Pharmaceuticals says prescriptions for chronic pain drug top 4,200 since launch - MSN
Tonix Pharma CEO Makes Bold Insider Move Signaling Growing Confidence - TipRanks
Tonix Pharmaceuticals (NASDAQ:TNXP) CEO Seth Lederman Acquires 15,000 Shares - MarketBeat
Tonix Pharmaceuticals to Present at BIO-Europe Spring 2026 - Bitget
Tonix Pharmaceuticals (TNXP) CEO adds 15,000 shares in open-market buy - Stock Titan
Tonix Pharmaceuticals Holding Corp Azioni (TNXP) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):